newsfilter
← Latest News
Business Wire·

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

EQ

EQ504 targets the aryl hydrocarbon receptor, a clinically validated pathway in the treatment of both skin and gastrointestinal diseases EQ504 has a unique, multi-modal, non-immunosuppressive mechanism of action that is